OLMESARTAN MEDOXOMIL Drug Patent Profile

Which patents cover Olmesartan Medoxomil, and when can generic versions of Olmesartan Medoxomil launch?

Olmesartan Medoxomil is a drug marketed by Accord Hlthcare, Alembic, Alkem Labs Ltd, Amneal, Aurobindo Pharma, Cadila Pharms Ltd, Chartwell Rx, Glenmark Pharms Ltd, Hetero Labs Ltd V, Inventia, Jubilant Generics, Lupin, Macleods Pharms Ltd, Micro Labs, MSN, Prinston Inc, Qilu, Rising, Sandoz, Sciegen Pharms, Sunshine, Teva Pharms Usa, Torrent, Umedica, Zydus Pharms, Hangzhou Binjiang, Natco Pharma Usa, Ph Health, and Piramal. and is included in forty-eight NDAs.

The generic ingredient in OLMESARTAN MEDOXOMIL is amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil. There are fifty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil profile page.

Summary for OLMESARTAN MEDOXOMIL

US Patents:	0
Applicants:	29
NDAs:	48
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLMESARTAN MEDOXOMIL

Paragraph IV (Patent) Challenges for OLMESARTAN MEDOXOMIL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BENICAR	Tablets	olmesartan medoxomil	5 mg, 20 mg and 40 mg	021286	1	2006-04-25

US Patents and Regulatory Information for OLMESARTAN MEDOXOMIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Umedica	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207135-003	Jul 18, 2019	AB	RX	No	No
Msn	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	217398-002	Sep 26, 2025	AB	RX	No	No
Micro Labs	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	206372-002	Sep 17, 2019	AB	RX	No	No

Investment Analysis of Olmesartan Medoxomil

Last updated: February 19, 2026

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) used primarily for hypertension management. Its market presence is driven by the global rise in hypertension prevalence, patent status, and competitive landscape involving other ARBs. This analysis covers market fundamentals, regulatory environment, patent considerations, and investment risks.

Market Fundamentals

Market Size and Growth

The global antihypertensive drugs market was valued at approximately $31 billion in 2021 and is projected to reach $45 billion by 2027 at a compound annual growth rate (CAGR) of 6.1% (Grand View Research, 2022). Olmesartan contributes an estimated 8% to 10% of the ARB segment, accounting for sales exceeding $1 billion annually.

Revenue Breakdown

Region	Market Share (%)	Estimated Sales (USD billion)
North America	35	350 million – 400 million
Europe	25	250 million – 300 million
Asia-Pacific	25	250 million – 300 million
Rest of World	15	150 million – 200 million

Competitive Position

Olmesartan is marketed under the brand Benicar by Daiichi Sankyo and by generic manufacturers post patent expiry. It faces competition from other ARBs such as losartan, valsartan, and newer agents like azilsartan. Its advantages include fewer side effects compared to first-generation ARBs but limited differentiation beyond existing incumbents.

Regulatory and Patent Landscape

Patent Expiry and Generic Entry

The original patent protection for olmesartan medoxomil in the United States expired in 2019. Generic versions entered the market thereafter, leading to a significant reduction in branded sales:

• Brand Name: Benicar
• Patent Expiry: US patent expired in June 2019
• Generics: Multiple manufacturers launched cost-effective alternatives

Regulatory Considerations

Olmesartan Medoxomil is approved in over 80 countries, with regulatory submissions approved by the FDA, EMA, and other agencies. Its safety profile, including risks of sprue-like enteropathy, has led to label updates but has not prevented widespread use.

Investment Risks and Opportunities

Risks

• Patent Cliff: Generic competition reduces profit margins and market share.
• Market Saturation: Many ARBs have similar efficacy; differentiation is limited.
• Regulatory Risks: Label updates and safety concerns may impact sales.
• Pricing Pressure: Increasing drug price transparency and biosimilar entry could erode revenues.

Opportunities

• Emerging Markets: Growing hypertension prevalence in Asia-Pacific offers expansion.
• Combination Therapies: Development of fixed-dose combinations may extend product lifecycle.
• New Formulations: Extended-release or combination pills could provide differentiation.

Strategic Recommendations

Healthcare companies should evaluate the diversification across hypertension therapeutics to mitigate patent expirations' impact. Investment in pipeline drugs that build on the olmesartan scaffold or target adjacent indications could buffer revenue decline.

Key Takeaways

• Olmesartan medoxomil entered patent expiry in 2019; generic competition dominates the market.
• The hypertensive drugs market is growing, but price competition intensifies.
• The drug remains relevant in emerging markets, providing long-term growth potential.
• Safety profile issues, including rare serious enteropathy cases, have affected labeling but have not significantly reduced use.
• Future growth hinges on pipeline development, combination therapies, and market expansion strategies.

FAQs

1. What is the main driving force behind olmesartan's market?
Growing prevalence of hypertension globally sustains demand, especially in emerging markets.

2. How has patent expiry affected olmesartan's revenues?
Branded sales declined sharply post-2019, with generics capturing over 80% of market share.

3. Are there any regulatory hurdles impacting olmesartan?
Label updates citing rare side effects have been issued, but no major regulatory barriers exist.

4. Which regions present the most growth opportunity?
Asia-Pacific and Latin America, due to increasing hypertension rates and low drug penetration.

5. What alternatives are investors considering amid patent expiration?
Focus shifts to fixed-dose combinations, biosimilars, and pipeline drugs with novel mechanisms.

---

References

[1] Grand View Research. (2022). Hypertension drugs market size & forecast.
[2] U.S. Food and Drug Administration. (2022). Drug label updates for olmesartan.
[3] Daiichi Sankyo. (2018). Benicar product information.